Disubstituted proline derivatives |
| We claim: 1. A compound of the formula I ##STR15## in which R.sup.1 and R.sup.2 together represent ... |
|
Carboxyalkyl dipeptides and anti-hypertensive use thereof |
| We claim: 1. A compound represented by the formula ##STR12## and the pharmaceutically acceptable ... |
|
Optically active bicyclic imino-alpha-carboxylic esters |
| We claim: 1. A compound of the formulae Ia or Ib essentially free of its racemate, and salts of ... |
|
5-HT.sub.3 receptor antagonists for treatment of cough and bronchoconstriction |
| I claim: 1. A method of treatment of cough and/or bronchoconstriction in mammals, which method ... |
|
Therapeutic compositions with enhanced bioavailability |
| OF THE INVENTION This invention relates to compositions of a drug with a water soluble polymer ... |
|
Medicament adsorbates and their preparation |
| In particular, it has been found that a good tasting medicament adsorbate is produced from ... |
|
Sustained release formulations |
| We claim: 1. In combination, a drug suitable for oral delivery and a delivery system for sustained ... |
|
Water dispersible gemfibrozil compositions |
| What is claimed is: 1. A water-dispersible formulation of gemfibrozil comprising finely divided ... |
|
Method and composition for enhancing the effect of indirect-acting sympathomimetic amines |
| OF SPECIFIC EMBODIMENTS In accordance with this invention, tyrosine or a tyrosine precursor such ... |
|
|
Solid oral dosage forms of ifosfamide
| Details |
Inventors: Sauerbier, Dieter; Engel, Jurgen; Milsmann, Eckhard; Molge, Klaus; Isaac, Otto;
Assignee: Asta Medica Aktiengesellschaft (DE)
Primary Examiner: Page; Thurman K.
Assistant Examiner:
Attorney, Agent or Firm: Cushman, Darby & Cushman
Solid oral ifosfamide formulations comprising a capsule containing a mass which consists essentially of the active substance ifosfamide and microcrystalline cellulose, or in the form of tablets which contain, in relation to one part by weight of ifosfamide, 0.1-1.0 parts by weight of tribasic calcium phosphate and 0.04-0.4 parts by weight of polyethylene glycol as well as in addition, related to the weight of the tablet 5-60% by weight of a filling and flow regulating agent 1-10% by weight of a disintegrant 0.1-10% by weight of an antiadhesion agent and 0.1-80% by weight of a binding agent. |
|
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS The invention is illustrated by the following examples: EXAMPLE 1 Ifosfamide capsule mass In accordance with the invention, the capsule mass is for example manufactured according to the following method: For 12,000 capsules of 250 mg each, 3. 0 kg ifosfamide, 1. 002 mg microcrystalline cellulose and 0. 018 kg highly disperse silicon dioxide are, for example, passed through a 0. 8 mm sieve and then mixed in a suitable mixer for 4 minutes. 0. 06 kg of magnesium stearate are then added to this mixture (sieved through a 0. 8 mm sieve) and mixing is repeated for i minute. The finished capsule mass is then dispensed with a capsule machine fitted with size 1 molds into size 1 hard gelatin capsules so that each capsule contains ca. 340 mg of the capsule mass. For 20,000 capsules of 500 mg each, 10. 0 kg ifosfamide, 3. 34 kg microcrystalline cellulose and 0. 06 kg highly disperse silicon dioxide are for example passed through a 0. 8 mm sieve and then mixed in a suitable mixer for 4 minutes-0. 2 kg of magnesium stearate are then added to this mixture (sieved through a 0. 8 mm sieve) and mixing repeated for 1 minute. The finished capsule mass is then filled in a capsule machine fitted with size 00 molds into size 00 hard gelatin capsules so that each capsule contains ca. 680 mg of the capsule mass. The microcrystalline cellulose is used for example in the form of Avicel PH 105. Avicel PH 105 has a special grain size spectrum and is a flowing substance with good binding and flowing properties. To manufacture gastric juice resistant capsules, a coating suspension in organic solvent (ifosfamide) is for example applied to 2500 size 1 capsules containing 250 mg ifosfamide. The 3000 g of suspension contain: 1440 g anionic polymerizate of methacrylic acid and methacrylic acid esters with a mean molecular weight of for example 150,000, to which a conventional softener has been added, 18 g of 1,2-propandiol, 36 g of magnesium stearate and 1506 g of isopropanol. The copolymerizate of methacrylic acid and methylmethacrylate that may for example be considered is Eudragit L
|
| Related patents |
|
|
[(benzodioxan, benzofuran or benzopyran) alkylamino] alkyl substituted guanidines
We claim: 1. A compound of the formula: ##STR259## a pharmaceutically acceptable acid addition salt thereof, or a stereochemically isomeric form thereof, wherein: X is O,...
|
|
|
Methods for treating dermatitis using descarboethoxyloratadine
OF THE INVENTION The present invention encompasses a method of treating allergic asthma in a human while avoiding the concomitant liability of adverse side-effects ...
|
|
|
Fat emulsions containing isocarbacyclin
What is claimed is: 1. A pharmaceutical prostaglandin emulsion comprising: a mixture of vegetable oil, phospholipid, water, and a pharmaceutically effective amount of at ...
|
|
|
Dermal pharmaceutical preparations
OF THE INVENTION The support which can be used in the present invention functions to retain a layer of a pressure-sensitive adhesive containing a drug and is selected ...
|
|
|
Substituted iminodiacids, their preparation and pharmaceutical compositions containing them
We claim: 1. A compound selected from the group consisting of iminodiacid compounds having the formula: ##STR20## wherein R.sub.1 represents lower-alkyl having 1 to 4 ...
|
|
|
2-Azasfiro[4.(3+N)]-3-carboxylic acid derivatives, a process for their preparation, agents containing these derivatives and their use
We claim: 1. A compound of the formula I ##STR11## in which n denotes 1, 2, 3 or 4, R denotes (C.sub.1 -C.sub.6)-alkyl, (C.sub.2 -C.sub.6)-alkenyl, (C.sub.5 -C.sub.9)-...
|
|
|
N-Acyl hexahydroindole-2-carboxylic acids and anti-hypertensive use thereof
We claim: 1. A compound of the formula I, ##STR24## in which n denotes 0 to 1, R denotes hydrogen, (C.sub.1 to C.sub.6)-alkyl or aralkyl having 7 to 9 C atoms, R.sup.1 ...
|
|
|
Bicyclic amino acids as intermediates in the preparation of tricyclic amino acids and processes for their preparation
We claim: 1. A compound of the formula III ##STR19## in which A denotes --CH.dbd.CH-- or --CH.sub.2 --CH.sub.2 --, the H atoms on C-2 and C-6 are in the cis-...
|
|
|
Substituted N-carboxymethyl-aminoacylaminoalkanoic acids useful as antihypertensive agents
OF THE INVENTION AND PREFERRED EMBODIMENTS In its broadest aspect, the present invention relates to novel substituted N-carboxymethyl-aminoacylaminoalkanoic acid ...
|
|
|
Racemates of optically active bicyclic imino-alpha-carboxylic esters
We claim: 1. A diasteromic salt of i. a bicyclic imino-.alpha.-carboxylic ester of the formulae Ia or Ib ##STR15## in which the two bridgehead hydrogen atoms have the ...
|
|
|